1) The Spy-2 protocol is explicitly meant to get drugs to cancer patients as soon as possible. If G works (and we have early indications that it does) it will be pushed through to breast cancer patients as quickly as possible.
2) Mr. Kovner is not just buying shares, he is collecting them (making it difficult for others to buy out?)
Fast-track designation is advantageous because it enables more-frequent interactions with the FDA regarding regulatory submission and review, as well as the possibility of accelerated approval, priority review, and rolling review.
Two very valid points.
Possibly a third point is that he is better informed on G potential,progress,and how close it could be to reality.
Another point is that the BOD may feel they need just $5MM...maybe less....and asked him(not him volunteering as that could be an ethics violation) if he had an interest in investing more money.
Last point......SNTA is definitely in an Elliot macro third wave up which means news could be next week or several months away.Regardless,I would not want to be shorting or day trading SNTA right now.
Is there money to be made by doing that?YEP........a helluva lot of risk too.
Interim analysis of phase II/III analysis of Ganestib in AML-LI is expected to be done first half of this year according to biopharmcatalystDOTcom. This may be the catalyst that can propel the next run